Table 2.
Prediction of HbA1c reductions in type 2 diabetic patients receiving GLP-1 RA.
| Model 1 | Model 2 | |||||
|---|---|---|---|---|---|---|
| B | SE | P value | B | SE | P value | |
| Bacteroides dorei | 0.431 | 0.125 | 0.001** | 0.397 | 0.119 | 0.002** |
| Lachnoclostridium sp. | 0.870 | 0.228 | <0.001*** | 0.647 | 0.202 | 0.003** |
| Butyricoccus sp. | 1.037 | 0.456 | 0.028* | NA | NA | NA |
| Prevotella copri DSM 18205 | -0.566 | 0.155 | 0.001** | -0.318 | 0.180 | 0.086 |
| Bacteroidales sp. | -1.184 | 0.257 | <0.001*** | NA | NA | NA |
| Mitsuokella multacida | NA | NA | NA | -0.755 | 0.264 | 0.007** |
| C-peptide | NA | NA | NA | 0.151 | 0.086 | 0.088 |
| Baseline HbA1c | NA | NA | NA | 0.540 | 0.099 | <0.001*** |
Model 1: microbial signatures only (R square = 0.593); Model 2: adjustment with clinical variables (R square = 0.724). B, regression coefficient; SE, standard error; NA, not applicable; HbA1c, glycohemoglobin. *P < 0.05; **P < 0.01; ***P < 0.001.